Our previous findings that AKT and SRC kinase inhibitors could cooperate with each other to reactivate the Rho-GAP and tumor suppressor activities of DLC1 in lung cancer lines expressing DLC1 protein8 implied it might be beneficial to use these two inhibitors singly or together in conjunction with Ixazomib or Tazemetostat for treatment. This evidence concerns the gene ARHGAP1 and lung carcinoma.